Last updated: August 3, 2025
Introduction
DYANAVEL XR 10 is an extended-release formulation of amphetamine aspartate mixed salts used primarily in treating Attention Deficit Hyperactivity Disorder (ADHD). Its unique pharmacokinetic profile offers extended symptom control, making it a preferred choice for many healthcare providers. As a controlled substance, DYANAVEL XR 10's supply chain demands strict adherence to regulatory standards, quality assurance, and reliable distribution channels. This article explores the key suppliers and manufacturing ecosystem supporting DYANAVEL XR 10, emphasizing the critical players, supply dynamics, and strategic considerations for stakeholders.
Manufacturing and Original Supplier
Tris Pharma, Inc. holds the patent rights and is the original manufacturer of DYANAVEL XR 10. The company's focus on controlled substance formulations and extensive R&D capabilities enable it to produce compliant, high-quality extended-release ADHD medications. Tris Pharma’s manufacturing facilities are situated to adhere to Good Manufacturing Practices (GMP) outlined by the FDA, ensuring product integrity throughout the supply chain.
Key aspects of Tris Pharma's supply chain include:
- Raw material sourcing from qualified suppliers who meet pharmacopoeia standards.
- In-house formulation development and quality control.
- Distribution network optimized for national and international markets.
Key Raw Material Suppliers
The production of DYANAVEL XR 10 hinges on several critical raw materials:
- Amphetamine Salts: Central to the formulation, sourced predominantly from specialized chemical suppliers capable of providing pharmaceutical-grade amphetamine salts conforming to USP standards.
- Excipients: Including extended-release matrix components, binders, and fillers supplied by global excipient manufacturers such as FMC, Evonik, and Ashland.
Contract Manufacturers and Co-Processing
In addition to Tris Pharma, other Industry players provide contract manufacturing and formulation services, often involved in:
- Blending and capsule filling: Contract manufacturers like Catalent, Patheon (a Thermo Fisher Scientific company), and Lonza often produce finished DYANAVEL XR 10 capsules under strict GMP compliance.
- Packaging and Labeling: Specialized packaging companies ensure tamper-proof, child-resistant, and compliant labeling, vital for controlled substances.
Distribution Channels and Suppliers
Distribution of DYANAVEL XR 10 involves a regulated network of distributors, specialty pharmacy partners, and pharmacies:
- Wholesalers: McKesson, Cardinal Health, and AmerisourceBergen serve as primary distributors, maintaining strict inventory controls for Schedule II controlled substances.
- Specialty Pharmacies: These often handle direct patient dispensing, especially under insurance plans or limited distribution protocols.
- Regulatory Compliance: All distributors operate under DEA regulations and possess necessary DEA registration to handle Schedule II drugs.
Regulatory and Supply Chain Challenges
Given the drug’s Schedule II classification, suppliers face the following challenges:
- Strict DEA Controls: Ensuring compliance with storage, record-keeping, and reporting mandates.
- Potential for Supply Disruption: Due to regulatory changes, manufacturing constraints, or raw material shortages.
- Counterfeit and Diversion Risks: Extensive vigilance and secure logistics are mandatory in the supply chain.
Emerging Suppliers and Market Dynamics
Recent trends highlight the entry of additional manufacturers in the ADHD stimulant market, driven by increased demand:
- Some generic companies, such as Teva Pharmaceuticals and Mylan (now part of Viatris), have developed licensed equivalents of extended-release amphetamine formulations. However, as of now, DYANAVEL XR 10 remains a proprietary product with limited direct competition.
- The development of biosimilars or alternative delivery systems could reshape the supplier landscape in the future.
Strategic Considerations for Stakeholders
- For Healthcare Providers: Verifying the authenticity of DYANAVEL XR 10 is critical due to the prevalence of counterfeit drugs in controlled substances.
- For Distributors: Implementing robust compliance protocols and monitoring supply chain security minimizes diversion risks.
- For Patients: Access to a consistent supply depends on supply chain resilience and manufacturer capacity.
Conclusion
The supply ecosystem for DYANAVEL XR 10 is characterized by a tightly regulated, multi-tiered network. Tris Pharma remains the core manufacturer, supported by a network of raw material suppliers, contract manufacturers, and distributors adhering to stringent regulatory standards. As demand for ADHD medications persists, suppliers’ capacity and compliance vigilance will be pivotal in ensuring uninterrupted patient access.
Key Takeaways
- Tris Pharma is the primary manufacturer of DYANAVEL XR 10, with a complex supply chain comprising raw material suppliers, contract manufacturers, and strict distribution networks.
- Raw materials, especially pharmaceutical-grade amphetamine salts and excipients, come from specialized global suppliers who meet rigorous pharmacopoeia standards.
- Regulatory compliance with DEA controls significantly influences suppliers' operational protocols, adding layers of security and oversight.
- Market dynamics indicate a steady demand, with potential new entrants in the ADHD medication space, though DYANAVEL XR 10 remains proprietary.
- Ensuring drug authenticity and supply chain security is critical for healthcare providers and distributors to prevent diversion and counterfeit risks.
FAQs
Q1: Who is the primary manufacturer of DYANAVEL XR 10?
A1: Tris Pharma, Inc. is the original and primary manufacturer of DYANAVEL XR 10.
Q2: What raw materials are critical in producing DYANAVEL XR 10?
A2: The key raw materials include pharmaceutical-grade amphetamine salts and various excipients used in extended-release formulations.
Q3: How does regulation affect suppliers of DYANAVEL XR 10?
A3: As a Schedule II controlled substance, suppliers must comply with DEA regulations governing storage, record-keeping, and distribution, increasing operational oversight.
Q4: Are there alternative suppliers or generics for DYANAVEL XR 10?
A4: Currently, DYANAVEL XR 10 is proprietary, with limited direct generic competition; however, other companies produce similar extended-release ADHD medications.
Q5: What challenges do supply chain disruptions pose for DYANAVEL XR 10?
A5: Disruptions can lead to shortages, impacting patient care. Risks include raw material shortages, regulatory changes, or logistical issues.
References
- FDA (2022). Drug Approval Packages.
- Tris Pharma Official Website. Product Portfolio.
- DEA (2023). Controlled Substance Schedules and Regulations.
- IQVIA (2022). Market Analysis and Trends in ADHD Medications.
- U.S. Pharmacopeia (USP). Standards for Pharmaceutical Raw Materials.
